Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma

Summary

This multicenter, open-label trial will randomize participants with multiple myeloma to a regimen of ibandronate or zoledronate in order to compare the incidence of nephrotoxicity, measured as creatinine clearance (CrCl) reduction greater than (\>) 30 percent (%) or an absolute value of 30 milliliters per minute (mL/min) or lower.

Timeline

Start

2006-02

Primary completion

2009-04

Completion

2009-04

Drugs

Indications